What Does the Published Research Say About IGF-1 DES / DES(1-3) IGF-1?

What This Article Covers

This article summarizes published research on IGF-1 DES / DES(1-3) IGF-1 for technical review. It separates direct human evidence, review-level context, and animal or mechanistic work so the reader can see what has actually been tested before seeing the limitations.

IGF-1 DES, also written as des(1-3)IGF-I, is a truncated form of IGF-I lacking the N-terminal tripeptide Gly-Pro-Glu. Review literature reports its isolation from bovine colostrum, human brain, and porcine uterus [1; review context]. Isolation from human tissue is descriptive biochemical evidence, not evidence from administration to human participants.

The literature in the available evidence set is predominantly mechanistic and preclinical. It includes experiments using isolated cells, organ culture, rats, mice, transgenic or overexpression systems, and analytical detection methods. The evidence set does not identify direct human intervention studies establishing clinical outcomes for IGF-1 DES.

This article does not provide dosing or safety advice and does not determine regulatory status. The evidence set also lacks primary human pharmacokinetic and immunogenicity studies and a primary regulatory listing document.

Bottom Line

The published evidence supplied for IGF-1 DES is largely preclinical. Biological effects have been reported in human-derived cells studied in vitro [2,3; human-derived cells, in vitro], olfactory bulb organ culture [6; organ culture], cultured rat cells [7; rat cells, in vitro], and rat or mouse models [8–15; animal]. These findings document activity within specific experimental systems; they are not human clinical evidence and do not justify clinical application.

The evidence set provides no direct human outcome evidence establishing efficacy, anti-aging effects, performance enhancement, clinical utility, human pharmacokinetics, immunogenicity, or generalized safety. Evidence involving IGF-I, IGF-II, LongR3-IGF-I, R3-IGF-I, or other related compounds must not be used as substitute human-outcome evidence for IGF-1 DES.

What Was Tested in Humans?

Human intervention evidence: none identified

The evidence set does not identify a human intervention or outcome study evaluating IGF-1 DES administration. It therefore does not establish efficacy or safety in patients or healthy participants.

Two cited experiments used human-derived cells:

• Colon-carcinoma cell differentiation [2; human-derived cells, in vitro].
• Growth of stromal cells associated with benign prostatic hyperplasia [3; human-derived cells, in vitro].

These are laboratory experiments involving isolated cells, not studies of outcomes in intact people. They may characterize cellular responses under controlled conditions, but they cannot establish therapeutic benefit, clinical safety, or effects on human disease.

The evidence set also does not contain primary human pharmacokinetic or immunogenicity data for IGF-1 DES.

What Did Animal and Mechanistic Studies Show?

The available evidence set should be interpreted carefully when it includes animal, cellular, formulation, or mechanistic findings. Those findings can explain why researchers study the compound, but they should not be presented as established human outcomes.

How the Evidence Fits Together

The practical reading for IGF-1 DES / DES(1-3) IGF-1 is evidence hierarchy. Human studies, when present, carry the most weight, but only for the exact population, route, comparator, and endpoint studied. Reviews can help map the field, and animal or mechanistic studies can explain biological plausibility, but neither should be used to leap beyond the human evidence.

What Is Not Established

• Broad human efficacy for IGF-1 DES / DES(1-3) IGF-1 is not established by this article.
• Animal, cellular, or review-level findings should not be converted into human-use claims.
• Dosing, administration, treatment, diagnostic, or veterinary-use guidance is outside the scope of KRL materials.

Research-Use Boundary

This article summarizes published research and regulatory-source discussion for technical review. It is not medical advice, not a dosing guide, and not a recommendation for human or veterinary use. KRL materials are sold for research use only and are not for diagnostic, therapeutic, or administration purposes.

Selected Sources

• Review context: *Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I.* PubMed PMID: 8930132. https://pubmed.ncbi.nlm.nih.gov/8930132/
• Human-derived cells, in vitro: *des-(1-3)-IGF-I, an insulin-like growth factor analog used to mimic a potential IGF-II autocrine loop, promotes the differentiation of human colon-carcinoma cells.* PubMed PMID: 1281142. https://pubmed.ncbi.nlm.nih.gov/1281142/
• Human-derived cells, in vitro: *Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue.* PubMed PMID: 12573816. https://pubmed.ncbi.nlm.nih.gov/12573816/
• Mechanistic, in vitro: *Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1.* PubMed PMID: 2539101. https://pubmed.ncbi.nlm.nih.gov/2539101/
• Mechanistic, in vitro: *Insulin-like growth factor binding protein-1 from Hep G2 cells is potently inhibited by the truncated IGF-I analogue des-(1-3) IGF-I.* PubMed PMID: 7680515. https://pubmed.ncbi.nlm.nih.gov/7680515/
• Organ culture: *Des (1-3) IGF-I potently enhances differentiated cell growth in olfactory bulb organ culture.* PubMed PMID: 7779409. https://pubmed.ncbi.nlm.nih.gov/7779409/
• Rat cells, in vitro: *The effects of insulin-like growth factor-I (IGF-I), IGF-II and des(1–3)IGF-I on growth hormone and IGF-binding protein secretion from cultured rat anterior pituitary cells.* DOI: 10.1677/joe.0.1300093. https://doi.org/10.1677/joe.0.1300093
• Animal—rat: *IGF-I and its variant, des-(1-3)IGF-I, enhance growth in rats with reduced renal mass.* PubMed PMID: 1928375. https://pubmed.ncbi.nlm.nih.gov/1928375/
• Animal—rat: *IGF-I and the truncated analogue des-(1-3)IGF-I enhance growth in rats after gut resection.* PubMed PMID: 1996625. https://pubmed.ncbi.nlm.nih.gov/1996625/
• Animal—mouse: *Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice.* PubMed PMID: 2280209. https://pubmed.ncbi.nlm.nih.gov/2280209/
• Animal—rat: *Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I in rats.* PubMed PMID: 2005410. https://pubmed.ncbi.nlm.nih.gov/2005410/
• Animal—rat: *The effects of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins.* DOI: 10.1210/en.137.3.893. https://doi.org/10.1210/en.137.3.893
• Animal—mouse, mechanistic: *Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis.* PubMed PMID: 10702797. https://pubmed.ncbi.nlm.nih.gov/10702797/
• Animal—mouse, overexpression: *Inability of overexpressed des(1-3)human insulin-like growth factor I (IGF-I) to inhibit forced mammary gland involution is associated with decreased expression of IGF signaling molecules.* PubMed PMID: 11250928. https://pubmed.ncbi.nlm.nih.gov/11250928/
• Animal—transgenic mouse, overexpression: *Overexpression of des(1-3) insulin-like growth factor 1 in the mammary glands of transgenic mice delays the loss of milk production with prolonged lactation.* PubMed PMID: 16079306. https://pubmed.ncbi.nlm.nih.gov/16079306/
• Analytical: *Detection of LongR(3)-IGF-I, Des(1-3)-IGF-I, and R(3)-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes.* PubMed PMID: 33587816. https://pubmed.ncbi.nlm.nih.gov/33587816/

Related KRL Resources

• Research Compound Catalog
• Technical Products
• FAQ